Drug Development Executive
Subscribe
Sign in
Home
Podcast
Notes
Clinical/Medical
Basic/Translational Sciences
Policy
Archive
Newsletters
About
Latest
Top
Discussions
Taltz+Zepbound : When Obesity Becomes a PK Problem
We Got the Synergy Story Backwards? Everyone: "GLP-1 + ixekizumab = immune synergy." Data: "Actually, ~70% of the benefit looks like weight loss fixing…
11 hrs ago
Would You Market a Drug You Can’t Explain?
(I probably will)
Feb 23
•
Eswar Krishnan, MD
1
CAR-T for Autoimmune Disease: A Safety Reckoning Is Coming – and the Field Is Not Ready
Graph showing adverse event rates in CAR-T therapy for lupus
Feb 9
•
Eswar Krishnan, MD
The unbearable lightness of AI written posts
There’s a little theatre that plays out on Substack, LinkedIn and other social media.
Feb 7
•
Eswar Krishnan, MD
1
2
January 2026
Atherosclerotic Plaque as a Lymphoid Organ
An introduction
Jan 15
•
Eswar Krishnan, MD
4
1
Forget CRP. Think Tregs
Low-Dose IL-2 Reduces Arterial Inflammation in ACS—Without Touching CRP
Jan 14
•
Eswar Krishnan, MD
1
Dear Medical Writing: It's Not You, It's the Algorithm
Dear Medical Writing,
Jan 13
•
Eswar Krishnan, MD
5
1
How to Turn a $200M Biosimilar Into a $1B Franchise
The formulation play that created a 20-year monopoly
Jan 8
•
Eswar Krishnan, MD
2
1
Bispecifics: Synergy That Can Be Modeled, Not Easily Verified
A case study of a α4β7 × TL1A bispecific
Jan 8
•
Eswar Krishnan, MD
1
The Algorithm in the Corner Office
Business Development for Medical Leaders Series – Part 1
Jan 3
•
Eswar Krishnan, MD
5
1
July 2025
State Of The Art in SLE: For Biotech CMOs and CSOs
Jul 18, 2025
•
Eswar Krishnan, MD
1
1
45:46
Is a pIND meeting always a prerequisite for success, or is it sometimes a bottleneck?
Jul 16, 2025
•
Eswar Krishnan, MD
1
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts